Article
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN - 1 Jan 2017
Greenberg Peter L, Stone Richard M, Al-Kali Aref, Barta Stefan K, Bejar Rafael, Bennett John M, Carraway Hetty, De Castro Carlos M, Deeg H Joachim, DeZern Amy E, Fathi Amir T, Frankfurt Olga, Gaensler Karin, Garcia-Manero Guillermo, Griffiths Elizabeth A, Head David, Horsfall Ruth, Johnson Robert A, Juckett Mark, Klimek Virginia M, Komrokji Rami, Kujawski Lisa A, Maness Lori J, O'Donnell Margaret R, Pollyea Daniel A, Shami Paul J, Stein Brady L, Walker Alison R, Westervelt Peter, Zeidan Amer, Shead Dorothy A, Smith Courtney
Abstract excerpt
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia,...
Topics
- Anemia
- Antineoplastic Agents
- Clinical Trials as Topic
- Hematinics
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunologic Factors